See Table 1 for characterization of the patients included in the analysis and the comparisons between groups. We found a significantly lower age for HC compared to MCI (p-value = 0.002, t-value = 3.187), and the mean MMSE was significantly lower in patients with AD (p-value < 0.001, t-value = −4.840) and MCI (p-value < 0.001, t-value = −4.646) compared to HC. Regarding medications, patients with MCI received significantly more antidepressants than HC (p-value < 0.05), while patients with AD received significantly more cholinesterase inhibitors (p-value < 0.001) compared to both HC and MCI. In AD, we found that CSF amyloid was significantly lower than in both MCI (p-value = 0.015) and HC (p-value < 0.001) and that it was significantly lower in MCI compared to HC (p-value 0.022). Furthermore, AD had a significantly higher concentration of CSF total tau compared to both MCI (p-value = 0.004) and HC (p-value < 0.001), and MCI showed a higher CSF total tau compared to HC (p-value = 0.012). The performance on cognitive screening instruments for baseline and at follow-up visit after 2 years with comparison between the scores can be seen in Table 2.
